Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EVAX Evaxion Biotech A/S

Closed 04-29 16:00:00 EDT

4.26

-0.06

-1.39%

盘后4.26

+0.000.00%

18:52 EDT

High4.37	Low4.08	Vol7.37K
Open4.35	D1 Closing4.32	Amplitude6.71%
Mkt Cap35.37M	Tradable Cap23.57M	Total Shares8.30M
T/O31.26K	T/O Rate0.13%	Tradable Shares5.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EVAX","market":"US","secType":"STK","nameCN":"Evaxion Biotech A/S","latestPrice":4.26,"timestamp":1777492800000,"preClose":4.32,"halted":0,"volume":7371,"hourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.26,"latestTime":"18:52 EDT","volume":30,"amount":123.9,"timestamp":1777503174626,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.013888888888889003,"floatShares":5531900,"shares":8302700,"eps":-1.202691,"marketStatus":"Closed","change":-0.06,"latestTime":"04-29 16:00:00 EDT","open":4.35,"high":4.37,"low":4.08,"amount":31263.617385,"amplitude":0.06713,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.202691,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777536000000},"marketStatusCode":5,"adr":0,"adrRate":50,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":4.32,"preHourTrading":{"tag":"盘前","latestPrice":4.18,"preClose":4.37,"latestTime":"04:00 EDT","volume":191,"amount":798.38,"timestamp":1777449608821,"change":-0.19,"changeRate":-0.043478,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.26,"latestTime":"18:52 EDT","volume":30,"amount":123.9,"timestamp":1777503174626,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.210801,"impliedVol":2.1042,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/EVAX","defaultTab":"news","newsList":[{"id":"2630391166","title":"BRIEF-Evaxion Promotes Birgitte Rønø To Joint Role Of Chief Scientific And Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391166","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630391166?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:48","pubTimestamp":1777294096,"startTime":"0","endTime":"0","summary":"BRIEF-Evaxion Promotes Birgitte Rn To Joint Role Of Chief Scientific And Chief Operating OfficerApril 27 (Reuters) - Evaxion A/S EVAX.O:EVAXION PROMOTES BIRGITTE RN TO JOINT ROLE OF CHIEF SCIENTIFIC A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA4XSXVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630939654","title":"Evaxion Promotes Birgitte RØNØ to Joint Role of Chief Scientific and Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630939654","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630939654?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA4XSXVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630113396","title":"Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630113396","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630113396?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281538/0/en/Evaxion-promotes-Birgitte-R%C3%B8n%C3%B8-to-joint-role-of-Chief-Scientific-and-Chief-Operating-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIYY","BK4139","BK4587","EVAX","BK4528","LU2272731782.SGD","CHAT","BK4551","AIPO","AI","LU1992135399.USD","BK4588","ARTY","LU1992135472.HKD","AGIX","GB00BDT5M118.USD","BK4023","COO","LU2211815571.USD","BK4198","BK4543","LU2272731600.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630382027","title":"Evaxion files Form 3 for director Jens Bitsch-Norhave###","url":"https://stock-news.laohu8.com/highlight/detail?id=2630382027","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630382027?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:20","pubTimestamp":1777065625,"startTime":"0","endTime":"0","summary":"Evaxion initial Form 3 disclosed director Jens Bitsch-Norhave holds 2,376 ordinary shares indirectly via Sprout Invest ApS as of April 16, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL70Hqfz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629237248","title":"European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2629237248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629237248?lang=en_us&edition=fundamental","pubTime":"2026-04-24 23:23","pubTimestamp":1777044216,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising late Friday morning, gaining 0.66% at 1,798.36 on the S&P Europe Select ADR Index, which is off 2% for the week so far.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk  and software firm SAP , which rose 6.4% and 5.6% respectively. They were followed by furniture maker Natuzzi  and consumer goods company Unilever , which were up 2.6% and 1.7% respectively.The decliners from continental Europe were led by biotech firm Evaxion  and petroleum refiner Equinor , which fell 2.4% and 1.4% respectively. They were followed by biopharmaceutical company Cellectis  and oil and gas company Eni , which were down 1.2% and 0.9% respectively.The gainers from the UK were led by British American Tobacco  and InterContinental Hotels Group , which advanced 2.5% and 2.4% respectively. They were followed by insurance company Prudential  and educational publisher Pearson , which increased 1.2% an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ULVR.UK","BK4588","BK4139","BK4095","EQNR","IHG","LU0124676726.USD","LU0689626769.HKD","UL","LU1093756325.SGD","BK4183","CLLS","NVOH","PSO","IE00BZ1G4Q59.USD","LU0162691827.USD","BK4007","TRIB","BK7062","BK4117","SLN","LU0154236417.USD","BK4599","BK4585","BK4075","BK4162","BK4592","IE00BKVL7J92.USD","NVOX","BK4613","NTZ","BTI","02378","BK4204","BK4023","BK4142","PUK","AUTL","BK4201","E","SAP","BK4107","LU2543165471.USD","BK7104","NCNA","LU0072461881.USD","LU1093756168.USD","BK4532","BK4111","UN","BK4082","BK4528","LU0006061336.USD","NVO","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629281007","title":"Evaxion Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629281007","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629281007?lang=en_us&edition=fundamental","pubTime":"2026-04-24 18:42","pubTimestamp":1777027320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2026 06:42 ET (10:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629904838","title":"Evaxion shareholders adopted 2025 annual report at annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629904838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629904838?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:03","pubTimestamp":1776855828,"startTime":"0","endTime":"0","summary":"Evaxion held annual general meeting April 16, 2026.Shareholders adopted audited annual report for fiscal year 2025.Authorization to issue warrants increased to nominal DKK 11,900,000; resolution passed.New authorization adopted to obtain loans via issuance of convertible loan notes up to nominal DKK 73,500,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6cKBNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629053914","title":"European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2629053914","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629053914?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:14","pubTimestamp":1776784468,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were falling sharply late Tuesday morning, dropping 1.15% to 1,812.72 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor  and internet browser company Opera , which rose 2.7% and 1.7% respectively. They were followed by 3D printer company Materialise  and medical device maker EDAP TMS , which were up 1.2% each.The decliners from continental Europe were led by biopharmaceutical company argenx  and pharmaceutical company Novo Nordisk , which fell 3% and 2.8% respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Ascendis Pharma , which were down 2.7% each.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics  and software firm Endava , which advanced 6.4% and 2.7% respectively. They were followed by education company Pearson  and pharmaceutical company Silence Therapeutics , which increased 1.2% and 0.9% res","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","OPRA","BK4023","BK4588","BK4134","NCNA","BDRX","BK4139","ASND","IE0034235188.USD","BK7104","BK4585","LU2324357040.USD","LU1983260115.SGD","NVO","IE00BZ1G4Q59.USD","BK4204","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00B2B36J28.USD","NVOX","BK4082","EDAP","CUK","IE0002141913.USD","NVOH","BK4546","IE00BKVL7J92.USD","LU0154236417.USD","DAVA","BK4599","BK4201","LU0084288595.USD","LU0648005311.SGD","IE0009355771.USD","BK4142","ARGX","EVAX","LU0320765992.SGD","MTLS","SLN","MREO","BK4505","BK4111","LU0889565916.HKD","LU1093756325.SGD","BK4107","EQNR","LU1093756168.USD","AKTX","IE00BFTCPJ56.SGD","PSO","BK4532","IE00BJJMRZ35.SGD","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628078992","title":"Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628078992","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628078992?lang=en_us&edition=fundamental","pubTime":"2026-04-18 03:15","pubTimestamp":1776453315,"startTime":"0","endTime":"0","summary":"Evaxion announces new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. The data will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-says-evx-01-demonstrates-86-vaccine-target-precision-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-says-evx-01-demonstrates-86-vaccine-target-precision-in-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIPO","BK4585","AIYY","BK4139","BK4551","EVX","BK4528","ARTY","BK4588","EVAX","AGIX","BK4587","BK4543","CHAT","BK4023","AI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628895527","title":"Evaxion’s AI-Immunology™ Platform Demonstrates 86% Vaccine Target Precision in Phase 2 Personalized Cancer Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628895527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628895527?lang=en_us&edition=fundamental","pubTime":"2026-04-18 03:10","pubTimestamp":1776453000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nTUA7M7PDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628789354","title":"Evaxion data show AI-Immunology platform designs glioblastoma vaccine targets, AACR presentation pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2628789354","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628789354?lang=en_us&edition=fundamental","pubTime":"2026-04-18 03:01","pubTimestamp":1776452465,"startTime":"0","endTime":"0","summary":"Evaxion reported new data supporting use of its AI-Immunology platform to design personalized cancer vaccines for glioblastoma.Results will be presented April 22, 2026, at AACR Annual Meeting in San Diego.Analysis with Duke University School of Medicine identified endogenous retrovirus-derived tumor targets as potential additions to glioblastoma vaccines.Findings also indicated mutation-derived targets suitable for inclusion in vaccines in most patients.Evaxion positioned data as proof-of-concept that its platform can broaden target selection in low-mutation tumors, potentially improving vaccine effectiveness.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL653zc1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628217795","title":"Evaxion Approves 2025 Report and Refreshes Board at April 16 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2628217795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628217795?lang=en_us&edition=fundamental","pubTime":"2026-04-17 00:28","pubTimestamp":1776356881,"startTime":"0","endTime":"0","summary":"Evaxion Biotech ( ($EVAX) ) has shared an announcement. On April 16, 2026, Evaxion A/S held its Annual General Meeting at its offices in Denmark, w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-approves-2025-report-and-refreshes-board-at-april-16-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-approves-2025-report-and-refreshes-board-at-april-16-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","BK4195","BK4229","XBI","BK4139","EVAX","BK4588","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627212656","title":"Evaxion elects Jens Bitsch Nørhave to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627212656","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627212656?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:37","pubTimestamp":1776353833,"startTime":"0","endTime":"0","summary":"Evaxion elected Jens Bitsch Nrhave to board of directors at annual general meeting.Shareholders re-elected Marianne Sgaard, Lars Holtug, Lars Aage Staal Wegner.Board seat also renewed for Roberto Prego Pineda.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLbMpW1b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627212582","title":"Evaxion held annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627212582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627212582?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:30","pubTimestamp":1776353418,"startTime":"0","endTime":"0","summary":"Evaxion held its Annual General Meeting on April 16, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL4bsKk9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4588","NDAQ","LU0314104364.USD","SG9999014021.USD","BK4139","EVAX","LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627212521","title":"Evaxion concludes Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627212521","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627212521?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:30","pubTimestamp":1776353400,"startTime":"0","endTime":"0","summary":"COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, held its Annual Gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275638/0/en/Evaxion-concludes-Annual-General-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4528","AIPO","BK4023","BK4139","AI","ARTY","AIYY","AGIX","BK4551","BK4587","EVAX","BK4543","CHAT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627447089","title":"European Equities Traded in the US as ADRs Rise in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2627447089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627447089?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:05","pubTimestamp":1776179126,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts rose late Tuesday morning with the S&P Europe Select ADR Index gaining 0.3% to 1,844.78.From continental Europe, the gainers were led by biopharmaceutical company Grifols  and internet browser company Opera , which rose 3.1% and 2.9%, respectively. They were followed by pharmaceutical company Novo Nordisk  and semiconductor company Sequans Communications , which were up 2.3% and 1.6%, respectively.The decliners from continental Europe were led by petroleum refiner Equinor  and biotech firm Evaxion , which fell 2.5% and 1.2%, respectively. They were followed by oil and gas company Eni  and pharmaceutical company Ascendis Pharma , which were down 1% and 0.5%, respectively.The gainers from the UK were led by biopharmaceutical companies Bicycle Therapeutics  and Biodexa Pharmaceuticals , which advanced 6.2% and 4.2%, respectively. They were followed by biopharmaceutical company NuCana  and cruise line operator Carnival , wh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1162221912.USD","DBE","BK4007","LU1093756168.USD","LU0098860793.USD","SHEH","BK4588","BK4082","BK7104","PXJ","LU0889565916.HKD","SQNS","DRIP","OPRA","USE","CUK","LU0300736492.USD","BK4075","BK4532","BK7062","DBC","BDRX","EQNR","TRIB","DIG","LU0278409577.USD","BK4201","IE00BKVL7J92.USD","LU0300736062.USD","BK4585","NVOX","BK4141","BK4139","GUSH","LU1093756325.SGD","LU2543165471.USD","IEO","BK4023","BTI","E","BK4142","LU0006061336.USD","NCNA","LU0320765992.SGD","BK4599","EVAX","LU0320765646.SGD","IXC","BCYC","LU0109394709.USD","LU0154236417.USD","LU2236285917.USD","VDE","IE00BZ1G4Q59.USD","GRFS","SHEL","NVOH","ASND","NVO","SLN","ERX","DRLL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627451298","title":"European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2627451298","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627451298?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:04","pubTimestamp":1776092679,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts began the week little changed late Monday morning, edging 0.02% higher to 1,822.16 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and telecommunications company Nokia , which advanced 26% and 9.3%, respectively. They were followed by furniture maker Natuzzi   and biotech firm Evaxion , which climbed 7.1% and 3.4%, respectively.The decliners from continental Europe were led by accommodations booking company trivago  and brewing company Anheuser-Busch InBev , which dropped 3.3% and 1.2%, respectively. They were followed by pharmaceutical company Sanofi  and lender Banco Santander , which were off 0.9% and 0.8%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics  and biopharmaceutical company Mereo BioPharma Group , which rose 7% and 4.8%, respectively. They were followed by biopharmaceutical companies NuCana","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BK4107","MREO","BK4207","BK4588","BK4505","BK4139","LNOK","BDRX","BK7119","BK4020","SAN.AU","BCYC","TRVG","SLN","BK4521","TRIB","NOK","SAN","BK7142","BUD","CLLS","BK4142","BCS","IE00BMPRXN33.USD","CUK","BK4077","BK4585","IE00BMPRXR70.SGD","BK4082","AFG","BK4117","NCNA","BK4158","SNY","BK4095","EVAX","NTZ","BUD.AU","BK4007","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626010135","title":"European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2626010135","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626010135?lang=en_us&edition=fundamental","pubTime":"2026-04-09 23:14","pubTimestamp":1775747664,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.48% to 1,803.06 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and pharmaceutical company Ascendis Pharma , which advanced 4% and 3.1% respectively. They were followed by oil and gas company Eni  and telecommunications company Nokia , which increased 3% and 0.3% respectively.The decliners from continental Europe were led by biopharmaceutical company Grifols  and software firm SAP , which dropped 4.4% and 3.8% respectively. They were followed by internet browser company Opera  and biopharmaceutical company Cellectis , which lost 3% and 2.5% respectively.The gainers from the UK were led by biopharmaceutical company NuCana  and oil and gas company BP , which rose 5.5% and 2.2% respectively. They were followed by biotech firm Trinity Biotech  and biopharmaceutical company Amarin , which were up 1.8% and 0.5% res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRFS","BDRX","IE00BMPRXN33.USD","VDE","WPP.AU","E","SAP","BK4020","DBE","OPRA","NOK","ASND","SLN","USE","TRIB","EVAX","IE00BMPRXR70.SGD","DIG","BP","BK4547","BK4082","PXJ","IEO","BK4585","LNOK","AFG","BK4142","LU0162691827.USD","LU0320765646.SGD","DRLL","CLLS","BPH","CUK","BK4139","GUSH","LU1829250122.USD","ERX","AMRN","NCNA","BK4023","IXC","BK4009","LU0072461881.USD","BK4528","WPP","LU0889565916.HKD","DBC","BK4117","BK4588","DRIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953971","title":"Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953971?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:55","pubTimestamp":1775566509,"startTime":"0","endTime":"0","summary":"Evaxion (EVAX) has completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-reports-last-patient-visit-in-one-year-extension-of-evx-01-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-reports-last-patient-visit-in-one-year-extension-of-evx-01-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4581","XBI","BK4139","BK4588","EVX","EVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930948","title":"Evaxion completes phase 2 EVX-01 trial extension; three-year data due H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930948?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:04","pubTimestamp":1775563493,"startTime":"0","endTime":"0","summary":"Evaxion completed one-year extension of phase 2 trial for personalized cancer vaccine EVX-01 in advanced melanoma, marking last patient’s final physician visit.Three-year clinical efficacy results will be presented in second half of 2026.Earlier one- and two-year results were already presented, showing broad and durable tumor response with no relapses reported at two-year follow-up.Third-year follow-up tested EVX-01 as monotherapy, supporting assessment of standalone activity versus prior combination use with Keytruda.Evaxion said EVX-01 remained well tolerated, reinforcing its AI-designed vaccine approach as it builds a longer-term efficacy package.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9tKBDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evaxion.ai","stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":0.2273},{"period":"3month","weight":0.2169},{"period":"6month","weight":-0.25},{"period":"1year","weight":1.6182},{"period":"ytd","weight":-0.0943}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.312391},{"month":2,"riseRate":0,"avgChangeRate":-0.075072},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.067423},{"month":4,"riseRate":0.666667,"avgChangeRate":0.089842},{"month":5,"riseRate":0.4,"avgChangeRate":0.067918},{"month":6,"riseRate":0.2,"avgChangeRate":-0.044814},{"month":7,"riseRate":0.4,"avgChangeRate":0.060856},{"month":8,"riseRate":0.6,"avgChangeRate":-0.04913},{"month":9,"riseRate":1,"avgChangeRate":0.19717},{"month":10,"riseRate":0.4,"avgChangeRate":0.102065},{"month":11,"riseRate":0.2,"avgChangeRate":-0.236379},{"month":12,"riseRate":0,"avgChangeRate":-0.21322}],"exchange":"NASDAQ","name":"Evaxion Biotech A/S","nameEN":"Evaxion Biotech A/S","securityTypeName":"DR","adrRate":"1:50"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evaxion Biotech A/S,EVAX,Evaxion Biotech A/S股票,Evaxion Biotech A/S股票老虎,Evaxion Biotech A/S股票老虎国际,Evaxion Biotech A/S行情,Evaxion Biotech A/S股票行情,Evaxion Biotech A/S股价,Evaxion Biotech A/S股市,Evaxion Biotech A/S股票价格,Evaxion Biotech A/S股票交易,Evaxion Biotech A/S股票购买,Evaxion Biotech A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction